NORML is pleased to present the latest expanded/updated edition of the publication Emerging Clinical Applications for Cannabis & Cannabinoids — a comprehensive review of the latest peer-reviewed science specific to the safety and therapeutic efficacy of whole-plant cannabis and/or its components.
One-quarter of patients with multiple sclerosis report having used cannabis therapeutically and nearly one out of six (16 percent) currently use it to treat symptoms of the disease, according to survey data commissioned by the North American Research Committee on MS. Those with more advanced symptoms of MS were more likely to report using cannabis therapeutically.
The consumption of legal hemp seed nutritional oil, in conjunction with the intake of evening primrose oils and a restrictive diet high in Hot-natured foods (such as pepper) and low in saturated fats and sugars, is associated with “significant improvement” in symptom management and immunological characteristics in subjects with multiple sclerosis, according to clinical trial data published this month in the scientific journal BioImpacts.
#1 Colorado and Washington Vote To Legalize Marijuana Voters in Colorado and Washington made history…
For the second time in recent months, a scientific paper published in a peer-reviewed journal…
[Editor’s note: This post is excerpted from this week’s forthcoming NORML weekly media advisory. To…
Is it any wonder that the US government fights tooth-and-nail to hinder researchers’ attempts to…
Earlier this week Drug Czar Gil Kerlikowske sat down for a face-to-face interview with The…
NORML has recently posted online the fourth edition of its popular and comprehensive booklet, “Emerging…